Calix Limited

The Business

Calix holds roughly a quarter of the US magnesium hydroxide (MgOH) market for water treatment, running nine plants across an integrated mine-to-customer supply chain that most competitors cannot replicate. This Magnesia division generates 95% of group revenue. Alongside it sit three pre-commercial technology platforms (Leilac, Zesty, ZEAL) targeting cement, iron and mining decarbonisation, backed by partnerships with Rio Tinto, Hydro and Adani. The technology division has consumed roughly $9 million a year in cash without producing a single licensing contract.

Recent Performance

Calix has fallen sharply from its 2021-22 cleantech peak, when speculative capital chased decarbonisation stories at multiples several times higher than today's. FY26 revenue rose 28% to $36.0 million, driven by Magnesia's 41% growth, but the group posted a net loss of $51.6 million including a $30.3 million impairment on a joint venture. Management responded with a 24% cut to operating expenses and an 80% reduction in capital spending.

Outlook

Magnesia's revenue is expected to keep compounding over the next several years, though growth should decelerate as US market share approaches its practical ceiling. Group EBITDA losses are expected to narrow over the same period as technology platform costs wind down, but the business is not expected to reach cash flow breakeven within the next few years. Free cash flow is likely to remain negative for some time yet.

Key Risks

Cash runway of 11-17 months creates dilution risk if milestone payments slip. Twenty years without licensing revenue means the technology platforms' option value remains largely theoretical. Two customers exceed 10% of group revenue, and a single US contract represents 29% of Magnesia's sales, a concentration that leaves the growth trajectory exposed to a single relationship.

What to Watch

The thesis-defining event is Calix's H1 FY27 result in February 2027, which will confirm whether Magnesia's growth trajectory holds through the first half of the year.

• Feb 2027 H1 FY27 Magnesia revenue — confirms or breaks the growth trajectory underpinning the current outlook.
• 2-4 years First technology licensing agreement — would fundamentally reprice the equity if achieved.

Company Description

Calix operates two distinct businesses under one listed entity. Magnesia produces magnesium hydroxide and related specialty chemicals for water and wastewater treatment, contributing 95% of group revenue ($34.3 million in FY26) through nine manufacturing plants across the US and Australia. The technology division comprises three pre-commercial platforms: Leilac (electric calcination for cement and lime decarbonisation), Zesty (green iron processing) and ZEAL (mining applications). These platforms contributed $1.7 million in FY26, mostly from paid engineering studies rather than product sales, and remain funded largely through government grants and partner capital.

Where the Growth Is

Magnesia is the growth engine, up 41% in FY26 to $34.3 million, with a multi-year runway still ahead of it. Growth is decelerating by design, from 20% toward the single digits over the coming years, as US market share approaches an estimated 30% ceiling of the addressable market. This trajectory is what drives the group toward eventual EBITDA breakeven, expected several years out rather than within the next few.

Competitive Position

Magnesia's advantage rests on an integrated mine-to-customer supply chain that embeds switching costs into customer dosing equipment, supporting 94% customer retention. Its US market share sits near 25% and is trending upward, positioning it as the number two domestic player in a niche with limited direct competition. This advantage should persist for five to seven years before either technology substitution or new entrants erode it, a stable but not indefinite position. The technology platforms carry substantial intellectual property (56 patent families across 20-plus years of R&D) but no demonstrated pricing power or commercial traction, so their competitive position remains unproven rather than defensible.

Management & Capital Discipline

Capital allocation has been inconsistent. A joint venture investment resulted in a $30.3 million impairment, a material destruction of shareholder capital. More recently, management has shown discipline: capital expenditure fell 80% to $2.1 million and operating expenses fell 24% in FY26. Management delivers reliably on Magnesia targets but has repeatedly slipped technology timelines, with the Leilac-2 project paused and an exclusivity arrangement with Heirloom lost. Forward guidance on Magnesia deserves credibility; guidance on technology commercialisation timelines has a weaker track record and should be discounted accordingly.

Financial Position

Calix holds roughly $15.5 million in cash including a recent capital receipt, against an operating cash outflow of $11.4 million in FY26. This provides an estimated 11-17 months of runway depending on the timing of grant and milestone receipts. The auditor has flagged going concern as a key audit matter. The balance sheet cannot comfortably absorb a prolonged downturn or a delay in expected partner payments without a capital raise.